市場調查報告書
商品編碼
1466331
治療藥物監測市場:按產品、技術、藥物類別和最終用戶 - 2024-2030 年全球預測Therapeutic Drug Monitoring Market by Product (Consumables, Data Management Services, Equipment), Technology (Chromatography-MS, Immunoassays, Proteomic Technologies), Drug Class, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年治療藥物監測市場規模為37.9億美元,預計2024年將達43.8億美元,2030年將達到107.8億美元,複合年成長率為16.11%。
治療藥物監測是一種測量血漿、血清和血液中藥物濃度的實驗室檢驗過程。這些治療藥物監測過程允許設計患者特定的給藥方案、最佳化藥物功效以及維持患者體內藥物物質的恆定水平。慢性病的增加以及醫療保健和製藥行業的發展產生了對治療藥物監測的需求,以有效監測藥物的安全性和有效性。然而,熟練的實驗室技術人員數量有限和報銷政策不佳正在阻礙市場成長。此外,免疫測量和其他治療藥物監測技術的市場開拓正在創造市場成長機會。
主要市場統計 | |
---|---|
基準年[2023] | 37.9億美元 |
預測年份 [2024] | 43.8億美元 |
預測年份 [2030] | 107.8億美元 |
複合年成長率(%) | 16.11% |
產品高效藥品管理對資料管理服務的需求不斷成長
消耗品包括試劑、套件、校準曲線和其他一次性物品,這些物品對於提高藥物水平測試的準確性至關重要,並且由於重複使用而需求量很大。資料管理服務至關重要,它提供先進的解決方案來有效處理從 TDM 流程中獲得的大量資料。它還包括專為資料收集、分析和報告而設計的軟體和系統,以確保簡化關鍵患者和治療資訊的管理。設備領域包括用於特異性和靈敏藥物檢測的層析法和質譜檢測器、用於各種生物化學檢驗的臨床化學分析儀以及用於快速有效的藥物定量的免疫檢測分析儀,包括各種分析儀和檢測器。
最終用戶:醫院的需求不斷成長,準確的藥品管理至關重要
醫院實驗室有助於完善患者照護,特別是對於由於治療指數窄、毒性高或藥物代謝和作用的個體差異而需要精確劑量的治療。這種方法在急診環境和腫瘤學和移植醫學等專業中至關重要,其中精確的藥物管理對於患者的生存和康復至關重要。私人實驗室為更廣泛的門診病人提供服務,與初級保健和專家密切合作,管理心理健康、心血管疾病和自體免疫疾病等長期疾病。私人實驗室提供及時的藥物水平評估,並指導醫生做出有關劑量變化和藥物選擇的明智決定,幫助為患者量身定做有效的治療計劃,已成為實現這一目標的重要組成部分。
區域洞察
由於對器官移植的需求不斷成長、精準醫療的使用以及 TDM 在醫療保健領域(包括醫院和商業實驗室)的應用,美洲的市場格局正在迅速發展。慢性病盛行率的上升以及消費者對個人化藥物治療的偏好日益增加,顯著增加了亞太地區和歐洲、中東和非洲地區藥物開發過程中對治療藥物監測的需求。歐洲各國政府正在將重點轉向推出研發框架計劃,旨在開發新的個人化藥物,從而增加投資和資金籌措。世界各國政府都致力於加速開發各類藥物的基因組研究活動,認知到 TDM 的臨床益處將有助於最大限度地減少藥物副作用並改善治療結果,預計世界各地醫院對 TDM 的需求將會增加。得到
FPNV定位矩陣
FPNV定位矩陣對於評估治療藥物監測市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對治療藥物監測市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,以獲得市場競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.治療藥物監測市場的市場規模與預測為何?
2.治療藥物監測市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些?
3.治療藥物監測市場的技術趨勢和法規結構是什麼?
4.治療藥物監測市場主要廠商的市場佔有率為何?
5. 進入治療藥物監測市場的適當型態和策略手段是什麼?
[196 Pages Report] The Therapeutic Drug Monitoring Market size was estimated at USD 3.79 billion in 2023 and expected to reach USD 4.38 billion in 2024, at a CAGR 16.11% to reach USD 10.78 billion by 2030.
Therapeutic drug monitoring is the clinical testing process of measuring plasma, serum, or blood drug concentrations. These therapeutic drug monitoring processes enable designing the patient-specific dosage regimen, optimizing the effectiveness of drugs, and maintaining a certain level of drug substance in patients' bodies. The increase in chronic disease incidences and growth in the healthcare and pharmaceutical industries create the need for therapeutic drug monitoring to monitor drug dosage safety and efficacy effectively. However, the limited availability of skilled laboratory technicians and inadequate reimbursement policies is hampering the growth of the market. Furthermore, the developments in immunoassay and other therapeutic drug monitoring technologies are creating opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.79 billion |
Estimated Year [2024] | USD 4.38 billion |
Forecast Year [2030] | USD 10.78 billion |
CAGR (%) | 16.11% |
Product: Rising demand for data management services for efficient drug management
Consumables include indispensable disposable items such as reagents, kits, and calibrators, crucial for the accuracy of drug-level tests, and witness a growing demand due to their repetitive use. Data management services are pivotal, offering advanced solutions for efficiently handling the extensive data yielded from TDM processes, including software and systems designed for data collection, analysis, and reporting, ensuring streamlined management of crucial patient and treatment information. The equipment segment encompasses various analyzers and detectors, such as chromatography & MS Detectors for specific and sensitive drug detection, clinical chemistry analyzers for broad biochemical testing, and immunoassay analyzers for quick and effective drug quantification.
End-User: Increasing demand from hospitals where accurate drug management is essential
Hospital labs are instrumental in refining patient care, particularly for treatments requiring precise dosing due to the narrow therapeutic index, high toxicity, or individual variations in drug metabolism and action. This approach is essential in acute care scenarios and specialties such as oncology and transplant medicine, where accurate drug management is crucial to patient survival and recovery. Private laboratories cater to a broader outpatient population, collaborating closely with primary care and specialty physicians to manage long-term conditions, including mental health, cardiovascular, and autoimmune diseases. Private laboratories provide timely drug-level assessments and are indispensable in guiding physicians toward making educated decisions on dosage modifications and medication selection, thereby ensuring tailored and efficacious patient treatment plans.
Regional Insights
The therapeutic drug monitoring market shows a highly evolving landscape in the Americas owing to the increasing demand for organ transplantation, usage of precision medicines, and applications of TDM in healthcare areas, including hospital labs and private labs. The rising prevalence of chronic diseases, and increasing consumer switch towards personalized medications, tremendously increase the demand for therapeutic drug monitoring for drug development process in APAC and EMEA regions. European governments have shifted their focus towards launching the Framework Programme for Research and Technological Development, which aims to develop new personalized medicine leading to a rise in investment and funding. Governments worldwide are focusing on accelerating genomic research activities for the development of different types of drugs, and recognizing the clinical benefits of therapeutic drug monitoring is expected to raise demand for TDM from hospitals worldwide for better treatment outcomes with minimum side effects from the medication.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Therapeutic Drug Monitoring Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Therapeutic Drug Monitoring Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Therapeutic Drug Monitoring Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., apDia Group, ARK Diagnostics, Inc., ARUP Laboratories, Assay Genie, Bio-Rad Laboratories, Inc., bioMerieux SA, Buhlmann Laboratories AG, Cambridge Life Sciences Limited, Cardinal Health, Inc., Chromsystems Instruments & Chemicals GmbH, Danaher Corporation, DiaSorin SpA, DiaSystem Scandinavia AB, Eagle Biosciences, Inc., Exagen Inc., F. Hoffmann-La Roche AG, Grifols, S.A., H.U. Group Holdings, Inc., Krishgen Biosystems, Merck KGaA, Myriad Genetics, Inc., Neoteryx, LLC by Trajan Group, OneCare Media, LLC, Pfizer Inc., R-Biopharm AG, Randox Laboratories, Ltd., Sekisui Chemical Co Ltd., Siemens Healthineers AG, Svar Life Science AB, Tecan Trading AG, Theradiag SA, Thermo Fisher Scientific, Inc., and Veolia Group.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Therapeutic Drug Monitoring Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Therapeutic Drug Monitoring Market?
3. What are the technology trends and regulatory frameworks in the Therapeutic Drug Monitoring Market?
4. What is the market share of the leading vendors in the Therapeutic Drug Monitoring Market?
5. Which modes and strategic moves are suitable for entering the Therapeutic Drug Monitoring Market?